Egrifta (Tesamorelin) Seasonal Use Considerations

What Is Tesamorelin and Why Does Season Matter?

Tesamorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH). Administered as a 2 mg subcutaneous injection once daily, it stimulates the pituitary to secrete growth hormone (GH) in a pulsatile, physiologically normal pattern. The FDA approved tesamorelin under the brand name Egrifta in November 2010 specifically for reducing excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy. [1]

Season affects this drug in ways that are practical, physiologic, and pharmacokinetic. Ambient temperature threatens the stability of the reconstituted peptide. The GH/IGF-1 axis shows modest but measurable seasonal variation in published cohort studies. And real-world adherence data for daily injectable therapy consistently shows dips in summer travel months and the winter holiday period, both of which accelerate VAT rebound.

The Physiology Behind Seasonal GH Variation

Growth hormone secretion is not constant across the calendar year. A 2009 analysis of GH pulsatility data in healthy adults demonstrated roughly 10 to 15% lower mean overnight GH pulse amplitude in summer months compared with winter, attributed in part to longer photoperiod and elevated ambient temperature suppressing hypothalamic GHRH tone. [2] For patients on tesamorelin, this background variation means the drug is working against a slightly different endogenous axis depending on the season, a factor that clinicians rarely discuss but that may partly explain why some patients report slower VAT loss starting therapy in late spring versus autumn.

Why HIV Lipodystrophy Makes Seasonal Tracking More Complex

HIV-associated lipodystrophy produces a distinct phenotype: central VAT accumulation with peripheral fat loss, often worsened by older antiretroviral regimens containing thymidine analogs. This metabolic background means these patients already carry elevated fasting glucose, dyslipidemia, and cardiovascular risk at baseline. [3] Summer heat increases physical activity in some patients and reduces it in others. Dietary patterns shift. These changes can independently alter VAT volume, complicating the clinician's ability to attribute IGF-1 or body composition changes solely to tesamorelin dose fidelity.

Drug Storage and Reconstitution: Temperature Is the Primary Seasonal Risk

The single greatest seasonal hazard for tesamorelin is temperature excursion during storage or reconstitution. This is not a minor pharmacokinetic footnote; degraded peptide delivers no clinical benefit and exposes patients to the cost and access burden of wasted doses.

Unreconstituted Powder Storage

Egrifta lyophilized powder must be stored refrigerated between 2 and 8°C (36 and 46°F). It must not be frozen. [4] In winter, patients who store their medication in an unheated garage, near a drafty window, or in a car in freezing temperatures risk freeze-induced aggregation that renders the peptide inactive. Freezing does not always produce visible changes in the powder, so patients who freeze and thaw their vials cannot rely on visual inspection to detect degradation.

In summer, the inverse risk applies. A car interior in direct sun in July can exceed 60°C (140°F) within 20 minutes. Leaving a 30-day supply of Egrifta in a vehicle during a pharmacy pickup run is enough to compromise the batch.

Reconstituted Solution Stability

Once tesamorelin powder is reconstituted with sterile water, the resulting solution must be used within 3 hours and kept at room temperature, not above 25°C (77°F), during that window. [4] On a 90°F summer day without air conditioning, a reconstituted syringe sitting on a bathroom counter for 2 hours approaches or exceeds this limit. Patients traveling to warm climates or camping should be counseled to reconstitute immediately before injection, never in advance.

Travel and Seasonal Trips: A Practical Protocol

Summer vacations and winter travel both disrupt the refrigeration chain. Clinicians should review these steps with patients before any travel longer than 24 hours:

• Use an FDA-cleared insulated medication cooler with an ice pack, not dry ice (dry ice can freeze the vials).
• Carry Egrifta in carry-on luggage only. Checked baggage compartments can reach freezing temperatures at cruising altitude.
• At the destination, request a dedicated refrigerator space from the hotel or use a portable medical-grade cooler.
• If a temperature excursion is suspected, contact the dispensing specialty pharmacy before using the affected supply.

Seasonal Metabolic Changes and IGF-1 Monitoring

IGF-1 as the Primary Pharmacodynamic Marker

Tesamorelin's efficacy is tracked through serum IGF-1 levels. The FDA label instructs clinicians to obtain IGF-1 at baseline and then every 6 months during therapy. [4] The therapeutic window targets IGF-1 in the age- and sex-adjusted normal range; values persistently above the upper limit of normal (ULN) require dose reduction or discontinuation.

Seasonal variation in IGF-1 has been documented independently of any exogenous GH-axis stimulation. A longitudinal study of 128 healthy adults found IGF-1 concentrations approximately 8% higher in winter months than in summer, a difference the authors attributed to seasonal changes in insulin sensitivity, dietary protein intake, and sleep duration. [5] For a patient whose IGF-1 is sitting just below the ULN in February, a repeat level in August may be meaningfully lower for reasons unrelated to dose change. Conversely, a patient whose January IGF-1 looks therapeutic may have a July level that appears subtherapeutic without any adherence problem.

The clinical instruction is therefore to contextualize IGF-1 values by season when the absolute number is close to a decision boundary. A borderline-high February IGF-1 warrants a repeat in 6 to 8 weeks rather than an immediate dose change.

Body Composition Monitoring Across Seasons

Falutz et al. In the key NEJM 2007 trial (N=412) demonstrated that 6 months of tesamorelin 2 mg daily reduced VAT by 15.2% versus placebo using CT cross-sectional measurement at the L4-L5 level. [1] The 26-week assessment window aligns reasonably well with a single season, which means that if a patient starts tesamorelin in October, their 26-week efficacy CT falls in April, a period when many HIV-positive patients increase physical activity and reduce caloric intake, potentially obscuring the drug's independent contribution.

A subsequent 52-week extension from the same group confirmed that VAT reductions are maintained through 12 months of continuous therapy, but rebounded toward baseline within 26 weeks of discontinuation. [6] This rebound data reinforces why winter holiday nonadherence gaps of even 2 to 4 weeks can undo months of visceral fat reduction.

The HealthRX clinical team uses a seasonal anchor framework for tesamorelin monitoring: schedule the 26-week body-composition CT and IGF-1 check to land in spring (March to May) or fall (September to November), avoiding the summer travel peak and winter holiday period when appointment no-show rates in HIV specialty clinics are highest. This scheduling approach maintains measurement validity and reduces loss to follow-up.

Glucose and Metabolic Parameters: Seasonal Diet Effects

How Tesamorelin Affects Glucose

Tesamorelin can modestly increase fasting blood glucose and insulin resistance. The FDA label notes that new-onset diabetes mellitus occurred in 4.4% of tesamorelin-treated subjects versus 1.8% in placebo groups in the key trials. [4] GH-driven insulin antagonism is the mechanism. Clinicians should obtain fasting glucose and HbA1c at baseline, at 3 months, and at 6-month intervals thereafter.

Summer Dietary Shifts Compound Glucose Risk

Summer brings behavioral changes that can amplify tesamorelin's modest glycemic effect. Increased alcohol consumption, higher-sugar beverage intake, and irregular meal timing during vacation periods have all been linked to transient HbA1c elevation in metabolically vulnerable populations. [7] HIV-positive adults on modern antiretroviral therapy already carry a two- to fourfold higher prevalence of insulin resistance compared with HIV-negative controls. Adding tesamorelin during a period of dietary disruption does not preclude therapy, but it argues for a fasting glucose check 6 to 8 weeks after a summer vacation in patients with borderline baseline glucose values.

Winter Corticosteroid Use and GH Axis Blunting

Winter respiratory infections and sinusitis frequently prompt short-course corticosteroid use. Glucocorticoids suppress pituitary GH secretion and blunt the pituitary's response to exogenous GHRH stimulation. A 5-day burst of prednisone 40 mg/day can suppress GH pulsatility for up to 2 weeks after the last dose. [8] Patients on tesamorelin who require a steroid burst should not discontinue tesamorelin, but clinicians should not use an IGF-1 drawn within 2 weeks of completing a corticosteroid course as a reliable pharmacodynamic marker.

Adherence: The Seasonal Adherence Dip and Its Consequences

Daily subcutaneous self-injection is a high-burden regimen. Adherence to tesamorelin in the key extension trials was approximately 85% at 52 weeks among subjects who completed the trial. [6] Real-world adherence is lower. Specialty pharmacy refill data for injectable HIV-related therapies consistently shows 10 to 15% lower refill rates in June through August and again in late December, corresponding to vacation travel and holidays.

Why Missed Doses Matter More Than They Do for Small Molecules

Tesamorelin has a plasma half-life of approximately 26 minutes after subcutaneous injection, with biological activity mediated through downstream GH pulses and IGF-1 accumulation. [4] Unlike a small-molecule antiretroviral with a half-life of 12 to 40 hours, a single missed tesamorelin dose produces a genuine 24-hour gap in pituitary stimulation. Missing 5 doses in a 30-day month, which is a roughly 83% adherence rate, may not produce visible VAT rebound within that month, but the cumulative effect across two or three such months is detectable on CT imaging.

Adherence Support Strategies by Season

Summer strategies for maintaining adherence include:

• Pre-vacation specialty pharmacy coordination to ensure adequate supply before departure.
• Setting a phone alarm tied to a fixed daily routine that travels with the patient (morning shower, bedtime).
• Confirming refrigeration logistics with lodging before travel, not on arrival.

Winter strategies include:

• Holiday refill coordination 10 to 14 days before the dispensing pharmacy's holiday closure window.
• Reviewing injection technique after a multi-day adherence gap, since patients who pause sometimes develop technique anxiety on return.
• Checking storage conditions if the patient's home heating system fails during a cold snap.

Special Populations and Seasonal Considerations

Patients in Hot Climates

Patients residing in consistently hot climates, including the American Southwest, Florida, and tropical regions, face year-round versions of summer storage risk. For these patients, reconstitution immediately before injection is non-negotiable, and the use of a medical-grade home refrigerator with a temperature alarm is appropriate to discuss. The FDA has not issued specific stability data for sustained storage at temperatures exceeding 25°C, meaning out-of-range storage should always prompt a replacement request. [4]

Patients in Cold Climates

Patients in northern climates who heat their homes inconsistently, use older housing with cold spots near exterior walls, or leave medications in outbuildings face freeze risk. Tesamorelin should be stored in an interior-facing cabinet, never near an exterior wall or window. Patients should be explicitly told that frozen vials that have thawed may appear normal but are not safe to use.

Older Patients with HIV

HIV-positive adults over 60 years are the fastest-growing demographic in HIV care. This group tends to have lower baseline IGF-1, greater baseline insulin resistance, and a higher rate of seasonal mood and behavioral change that affects medication adherence. [9] The Endocrine Society guideline on GH use in adults (2011, updated) recommends more conservative IGF-1 targets in older patients and cautions against accepting IGF-1 values near the ULN without considering age-based normative adjustments. [10] For tesamorelin specifically, this means older patients need closer monitoring around seasonal IGF-1 swings.

Clinician Checklist: Seasonal Review Points for Tesamorelin Patients

The following actions should occur at any tesamorelin monitoring visit that falls near a seasonal transition:

Spring (March to May):

• Confirm winter storage was not compromised by freeze events.
• Review adherence log from November through February.
• Order IGF-1, fasting glucose, HbA1c.
• Schedule 26-week body composition CT if the patient started therapy in autumn.

Summer (June to August):

• Counsel on travel storage before any planned vacation.
• Order fasting glucose if diet history suggests significant behavioral change.
• Delay IGF-1 interpretation for 2 weeks after any corticosteroid course.

Fall (September to November):

• Ideal window for 26-week efficacy CT, given stable activity and diet.
• Reinforce adherence plan for the upcoming holiday period.
• Confirm specialty pharmacy holiday supply plan.

Winter (December to February):

• Review freeze-risk storage locations in the patient's home.
• Order IGF-1; note that winter values run 5 to 8% above summer norms.
• Check for recent corticosteroid use before interpreting IGF-1.

Discontinuation Decisions and Seasonal Timing

The FDA label states that tesamorelin should be discontinued in patients who do not demonstrate a VAT reduction after 26 weeks of therapy. [4] Clinicians should avoid scheduling the discontinuation-threshold CT scan during peak summer (July to August) or the winter holiday period, because patient no-show rates are highest then and rescheduling delays introduce ambiguity about exposure duration.

The Endocrine Society's 2011 clinical practice guideline on growth hormone in adults states: "Treatment should be discontinued if the patient does not demonstrate a clinically meaningful response after an adequate therapeutic trial." [10] For tesamorelin, the FDA has operationalized "meaningful response" as measurable VAT reduction on CT at 26 weeks, giving clinicians a concrete, imaging-confirmed endpoint rather than a symptom-based judgment.

The rebound kinetics described in the 52-week extension data are also seasonally relevant. Patients who discontinue in December, then reconsider in March after holiday weight gain, are not simply restarting from baseline. VAT reaccumulates toward pre-treatment levels within approximately 26 weeks of stopping. [6] Clinicians should communicate this clearly so patients do not interpret a planned holiday break as consequence-free.

Drug Interactions With Seasonal Relevance

Several drug classes used more commonly in specific seasons interact with the GH/IGF-1 axis in ways that are relevant to tesamorelin management.

Corticosteroids (winter respiratory season). As described above, short-course steroids suppress pituitary GH response for up to 2 weeks. Intranasal corticosteroids at standard doses have minimal systemic effect and are unlikely to alter IGF-1 meaningfully.

Non-steroidal anti-inflammatory drugs (NSAIDs). Increased NSAID use in summer (sports injuries, outdoor activity) has no direct GH-axis interaction, but NSAIDs in HIV-positive patients warrant renal function monitoring, and tesamorelin's downstream effects include mild fluid retention that may compound NSAID-related renal stress.

Antiretroviral therapy changes. If a patient switches antiretroviral regimen in winter or summer, new metabolic effects, particularly from integrase inhibitors associated with weight gain, may independently alter VAT and complicate the attribution of body composition changes to tesamorelin.

A 2019 analysis in JAMA found that integrase strand transfer inhibitor (INSTI)-based regimens were associated with a mean 2.2 kg weight gain over 96 weeks compared with non-INSTI regimens, with visceral fat representing a meaningful fraction of that gain. [11] Tesamorelin's 15% VAT reduction from the key trial may be partially offset in patients concurrently gaining VAT from an INSTI switch, making seasonal timing of regimen changes relevant to body composition monitoring.